Interstitial lung diseases (ILDs) are a group of disorders that can cause lung scarring, reducing oxygen transfer and making breathing difficult. The interstitium becomes thick and stiff, impairing gas exchange and progressively affecting respiratory function.
AbbVie will present new lung cancer data at WCLC 2026, including Phase 1b results for ABBV-1480 showing high response rates in NSCLC and safety updates for ABBV-706 in SCLC. The company also reported progress in dermatology, obesity, and Crohn's disease programs.
FDA approved zenocutuzumab-zbco (Bizengri) for NRG1 fusion-positive cholangiocarcinoma on May 8, 2026. The eNRGy trial showed a 36.8% ORR. It also received priority review, breakthrough, and orphan designations.
FDA approves AstraZeneca and Daiichi Sankyo's Datroway for first-line TNBC patients not eligible for PD-1/L1 inhibitors, based on Phase III TROPION-Breast02 data showing a 21% reduction in risk of death versus chemotherapy.
Datopotamab deruxtecan improved PFS and OS versus chemotherapy in advanced TNBC in TROPION-Breast02. Median PFS was 10.8 vs 5.6 months; OS was 23.7 vs 18.7 months. Published in Annals of Oncology.
The FDA has approved Lifyorli (relacorilant) plus nab-paclitaxel for platinum-resistant ovarian cancer based on trial data showing improved survival. Separately, the agency granted Breakthrough Therapy designation to Lilly's sofetabart mipitecan for the same condition, expediting development of the antibody-drug conjugate.
Trastuzumab deruxtecan is moving into earlier treatment lines for HER2-positive metastatic breast cancer, demonstrating superior efficacy over standard regimens and prompting reconsideration of long-standing treatment sequences.
The FDA has expanded approval of GSK's Arexvy RSV vaccine to include adults aged 18 to 49 years at increased risk for lower respiratory tract disease, based on phase 3b trial data showing noninferior immune response.
AIM ImmunoTech partners with Thermo Fisher to design Phase 3 trial for Ampligen in pancreatic cancer, while Innovent Biologics begins dosing patients in Phase 3 study of IBI354 for HER2-positive breast cancer.
Insmed reported total revenues of $606.4 million for 2025, with ARIKAYCE growing 19% annually. The FDA granted orphan drug designation to treprostinil palmitil for pulmonary arterial hypertension treatment in January 2026.
A 24-year-old woman with refractory lupus achieved two successful pregnancies following dual-target CAR-T cell therapy, while bispecific T cell engagers showed efficacy in treatment-refractory antisynthetase syndrome and systemic sclerosis patients.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07775235 |
Treatment Response in Immune-mediated Myositis Associated Rapidly-progressing Interstitial Lung Disease |
RECRUITING | |
| NCT07761377 |
Retrospective Validation of AccuPulmo CT Portal for Detecting Pulmonary Fibrosis on Chest CT |
RECRUITING | |
| NCT07728448 |
Predictors of Pulmonary Embolism in Interstitial Lung Disease With Worsening Symptoms |
NOT_YET_RECRUITING | |
| NCT07714252 |
Virtual Nurse and Social Worker Palliative Care Team to Improve Quality of Life in Veterans With Heart Failure or COPD |
NOT_YET_RECRUITING | NA |
| NCT07712952 |
Validation of AI-Based Detection of Idiopathic Pulmonary Fibrosis in Serial Chest Radiographs: A Retrospective Longitudinal Study |
COMPLETED | |
| NCT07613099 |
Fibrotic Disease Activity in Cardiopulmonary Disorders Using 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) PET/CT Imaging |
RECRUITING | PHASE3 |
| NCT07572383 |
Advanced Imaging to Assess the Effect of Immunosuppression on Progressive Fibrosis |
RECRUITING | PHASE2 |
| NCT07561034 |
The Benefits of Home Exercise in Pulmonary Hypertension Interstitial Lung Disease |
RECRUITING | NA |
| NCT07541638 |
Early Recognition of Progressive Lung Fibrosis in Systemic Rheumatic Diseases |
RECRUITING | NA |
| NCT07512687 |
Titrated Ambulatory Oxygen in Fibrotic ILD and COPD With Isolated Exertional Hypoxemia |
RECRUITING | NA |
